Here’s what you should know.
1. CMS introduced the proposal during the summer of 2016. Pharmaceutical, medical and patient advocate lobbyist groups have criticized it prompting President Obama to recently abandon the measure.
2. President Obama promoted the proposal chiding the pharmaceutical industry for opposing changes to prescription costing.
3. The lobbyist groups “accused the administration of interfering in the doctor-patient relationship and possibly endangering the lives of patients,” The Fiscal Times report read.
4. Republican and Democratic members of the Senate Finance committee supported the lobbying groups. Twenty-four House Democrats were also against the plan including Nancy Pelosi (D-Calif.).
More articles on coding, billing and collections:
MACRA patient engagement cheat sheet No. 4: Patient engagement strategies for bundled payments
ACA enrollment hits 4M: 3 takeaways
Humana CEO highlights company’s relationship with Aetna during trial
